Johnson & Johnson seeks FDA approval for Tremfya for Crohn’s disease
Johnson & Johnson (J&J) has submitted an sBLA seeking approval from the US FDA for Tremfya (guselkumab) to treat Crohn’s disease.
Johnson & Johnson (J&J) has submitted an sBLA seeking approval from the US FDA for Tremfya (guselkumab) to treat Crohn’s disease.
What's Your Reaction?
